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ABSTRACT
Background: Several recent studies have suggested
that oestrogen exposure may increase the risk of
prostate cancer (PCa).
Objectives: To examine associations between PCa
incidence and mortality and population-based use of
oral contraceptives (OCs). It was hypothesised that OC
by-products may cause environmental contamination,
leading to an increased low level oestrogen exposure
and therefore higher PCa incidence and mortality.
Methods: The hypothesis was tested in an ecological
study. Data from the International Agency for Research
on Cancer were used to retrieve age-standardised rates
of prostate cancer in 2007, and data from the United
Nations World Contraceptive Use 2007 report were
used to retrieve data on contraceptive use. A Pearson
correlation and multivariable linear regression were
used to associate the percentage of women using OCs,
intrauterine devices, condoms or vaginal barriers to
the age standardised prostate cancer incidence and
mortality. These analyses were performed by individual
nations and by continents worldwide.
Results: OC use was signiﬁcantly associated with
prostate cancer incidence and mortality in the
individual nations worldwide (r¼0.61 and r¼0.53,
respectively; p<0.05 for all). PCa incidence was also
associated with OC use in Europe (r¼0.545, p<0.05)
and by continent (r¼0.522, p<0.05). All other forms of
contraceptives (ie, intra-uterine devices, condoms or
vaginal barriers) were not correlated with prostate
cancer incidence or mortality. On multivariable
analysis the correlation with OC was independent of
a nation’s wealth.
Conclusion: A signiﬁcant association between OCs
and PCa has been shown. It is hypothesised that the
OC effect may be mediated through environmental
oestrogen levels; this novel concept is worth further
investigation.
INTRODUCTION
Prostate cancer (PCa) is the most common
male malignancy in the Western world, and
risk factors associated with this cancer remain
ill deﬁned.
1 The only acknowledged risk
factors thus far are: age, ethnicity and family
history.
1 Several studies have suggested that
oestrogen exposure may increase the risk of
prostate cancer,
2e4 while other studies have
not found an association.
56
The use of oral contraceptives (OCs) has
exploded over the past 40 years and has had
a patchy uptake in terms of global utilisation.
Emerging literature suggests that OC use may
be associated with a variety of medical
conditions among consumers, such as athe-
roembolic disease and even breast
cancer.
7e10 Aside from disease risk among
actual drug consumers, there is also
increasing concern about environmental
contamination by endocrine disruptive
compounds (EDCs) and their association
with diseases of increasing incidence such as
breast cancer (men and women), early
onset puberty and testicular cancer. EDCs
include a variety of compounds used in
commercial applications, such as detergents,
pesticides, cosmetics and building mate-
rials.
11 It is plausible that by-products of
OC metabolism could be passed via
urine into the environment in general or
drinking water, thus exposing the population
at large.
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ARTICLE SUMMARY
Article focus
- Several recent studies have suggested that
oestrogen exposure may increase the risk of
prostate cancer (PCa).
- Associations between PCa incidence and
mortality and population-based use of oral
contraceptives (OCs) have been examined.
- It is hypothesised that OC by-products may
cause an environmental contamination, leading
to an increased low level oestrogen exposure and
therefore higher PCa incidence and mortality.
Key messages
- In this hypothesis generating ecological study,
a signiﬁcant association between female use of
OCs and prostate cancer has been demonstrated.
Strengths and limitations of this study
- This study is an ecological study and thus has
signiﬁcant limitations with respect to causal
inference. It must be considered hypothesis
generating, and thought provoking.
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Open Access ResearchIn this report we examine associations between pros-
tate cancer incidence and mortality and population-
based use of OCs. In addition, to explore the speciﬁc
effect of OCs, we also examined these outcomes in
association with other modes of contraception.
METHODS
Study design and data sources
This study utilised a geographic or ecological design to
identify associations between aggregate use of contra-
ception and rates of prostate cancer. We utilised data
from the International Agency for Research on Cancer to
retrieve age-standardised rates of country-speciﬁc prostate
cancer incidence and mortality in 2008.
12 The incidence
data are derived from population-based cancer registries.
These mostly cover entire national populations but may
cover smaller, subnational areas, and, particularly in
developing countries, only major cities. While the quality
of information from most of the developing countries
might not be of sufﬁcient quality, this information is often
the only relatively unbiaised source of information
available on the proﬁle of cancer in these countries.
The United Nations World Contraceptive Use 2007
report
13 was used to retrieve data on contraceptive use.
In this report, data were obtained from surveys of
nationally representative samples of women of repro-
ductive age. The estimates for each nation represent
weighted averages derived for each country by the esti-
mated number of women aged 15e49 in 2007 who are
married or in union. These estimates are based on data
on the proportion of women married or in union in
each country contained in the World Marriage Database
2006
14 and on estimates of the number of women by age
group obtained from World Population Prospects: The
2006 Revision.
15 Again information may be less accurate
for developing countries; however, this is the best avail-
able information on contraceptive use.
The following information was collected: percentage
of woman of reproductive age using OCs, intrauterine
devices, condoms or vaginal barriers. The rationale for
examining alternate uses of birth control was to examine
speciﬁcity for OCs, as it is plausible that this measure is
a marker of sexual activity, which itself has demonstrated
some inconsistent association with prostate cancer.
16 In
addition to global incidence and mortality, we also
examined continent speciﬁc and Europe speciﬁc
outcomes as we wanted to test this association among
a more homogenous group with narrower ranges of both
OC use and prostate cancer incidence/mortality.
We also used data from The World Factbook (ISSN
1553-8133; also known as the CIA World Factbook) to
retrieve information on gross domestic product (GDP)
per capita in each country.
17 GDP refers to the market
value of all ﬁnal goods and services produced in
a country in a given period. GDP per capita is often
considered an indicator of a country’s standard of living.
We used this data to control for prostate cancer
screening tendencies since countries with a higher GDP
are more prone to PCa screening.
The World Factbook is prepared by the CIA for the use
of US government ofﬁcials. However, it is frequently
used as a resource for academic research papers.
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Figure 1 Correlation between prostate cancer (PCa)
incidence expressed as age standardised per 100000 persons
and percentage of contraceptive use in women aged 15e49, in
individual nations: worldwide (A), in Europe (B), and by
continent (C).
2 Margel D, Fleshner NE. BMJ Open 2011;1:e000311. doi:10.1136/bmjopen-2011-000311
Oral contraceptives increase the risk of prostate cancerStatistical analysis
Pearson correlation was used to associate age-adjusted
prostate cancer incidence and mortality rates to the
percentage of women using OCs, intrauterine devices,
condoms or vaginal barriers. We performed these analyses
by individual nations and by continents worldwide. We
randomly identiﬁed 87 different nations for the survey,
ensuring sampling of each continent (the list of countries
included in the analysis can be found in appendix 1). We
used 50% of countries available from each continent (25
of 50 in Africa, 25 of 50 in Asia, 24 of 47 in Europe, and 11
of 23 in America, Australia and New Zealand were also
included). We did not use all available countries since we
aimed at a equal representation of developed and under-
developed countries (using the entire sample would have
caused over-representation of under-developed countries
and may have biased our results).
We performed a linear regression model to assess
whether mode of contraceptive use is associated with
prostate cancer incidence; mortality variables included
in our model were: percentage of women of reproduc-
tive age using OCs, intrauterine devices, condoms or
vaginal barriers; and GDP per-capita in each nation.
Probability values <0.05 were deemed signiﬁcant.
RESULTS
As shown in ﬁgure 1AeC, OC use was signiﬁcantly
correlated with prostate cancer incidence in the indi-
vidual nations worldwide (ﬁgure 1A;r ¼0.61, p<0.05), in
Europe (ﬁgure 1B;r ¼0.545, p<0.05), and by continent
(ﬁgure 1C;r ¼0.522, p<0.05). All other forms of
contraceptives (ie, intrauterine devices, condoms or
vaginal barriers) were not correlated with prostate
cancer incidence.
Mortality correlated with OC use in the individual
nations worldwide (ﬁgure 2A;r ¼0.53, p<0.05). However,
no correlation was found in prostate cancer mortality
rates within Europe or by continent. In addition we did
not demonstrate any correlation between other modes
of contraceptives and prostate mortality rates.
Table 1 shows the multivariable analysis of the associ-
ation of PCa incidence and mortality with mode of
contraceptives controlling for GDP per-capita. As shown,
both incidence and mortality were associated with OC
use even after controlling for an indicator of a country’s
wealth (adjusted estimate 1.06 (95% CI 0.58 to 1.6) and
0.75 (95% CI 0.31 to 1.1), for incidence and mortality
respectively; p<0.01 for all).
DISCUSSION
In this study we have shown a strong correlation between
the country-speciﬁc female OC use and incidence of
prostate cancer among worldwide, continent and even
intra-European nations. This correlation appeared
speciﬁc to OC as no association was demonstrated with
other forms of contraception such as intrauterine
devices, condoms or vaginal barriers. Furthermore,
prostate cancer mortality was also associated with OC use
when examined globally. The correlation to OC use was
independent of GDP as a measure of a country’s wealth,
and strongest in Europe.
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Figure 2 Correlation between prostate cancer (PCa)
mortality expressed as age standardised per 100000 persons
and percentage of contraceptive use in women aged 15e49, in
individual nations: worldwide (A), in Europe (B), and by
continent (C). IUD, intrauterine device.
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Oral contraceptives increase the risk of prostate cancerThis study represents the ﬁrst systematic analysis of
associations between OC use and prostate cancer. It is an
ecological study and thus has, as with all correlational
studies, signiﬁcant limitations with respect to causal
inference.
18 As such, it must be considered hypothesis
generating.
There are several plausible explanations for this asso-
ciation. Prostate cancer has been associated with sexual
transmission. Although no particular infectious agent
has been identiﬁed, recent interest in the xenotropic
murine leukaemia virus-related virus and its discovery in
semen has raised this as a possible candidate.
17 19 Clearly
more studies are needed. We would hypothesise,
however, that if sexual activity were the explanation for
the above observations, similar outcomes would be
noted for other forms of contraception and that one
could even assume a protective effect. As we do not have
individual level data, these hypotheses are not testable
and would require a long latency period.
Another plausible explanation for the association
between OC use and prostate cancer is the potential
environmental impact of OCs. The last two decades have
witnessed growing scientiﬁc concerns and public debate
over the potential adverse effects that may result from
exposure to a group of chemicals that have the potential
to alter the normal functioning of the endocrine system
in wildlife and humans. These chemicals are typically
known as endocrine disturbing compounds (EDCs).
Temporal increases in the incidence of certain cancers
(breast, endometrial, thyroid, testis and prostate) in
hormonally sensitive tissues in many parts of the indus-
trialised world are often cited as evidence that wide-
spread exposure of the general population to EDCs has
had adverse impacts on human health. OCs in use today
can potentially act as EDCs as they frequently contain
high doses of ethinyloestradiol, which is excreted in
urine without degradation. This can then end up either
in the drinking water supply or passed up the food
chain.
11 OCs were made publicly available in the 1960s,
and have been widely used since the 1980s, hence the
exposure to these substances, even in small quantities,
may be chronic enough (20e30 years) to have a clini-
cally signiﬁcant effect.
There are limited epidemiological data that have
examined associations between prostate cancer and
exposure to environmental EDCs. These are largely
derived from occupational exposures, and many lack
internal exposure information. In one retrospective
cohort epidemiology study of Canadian farmers linked
to the Canadian National Mortality Database, a weak but
statistically signiﬁcant association between acres sprayed
with herbicides and prostate cancer deaths was found.
20
Multigner et al
21 have recently demonstrated that envi-
ronmental exposure to chlordecone, an organochlorine
insecticide with well deﬁned oestrogenic properties,
increases the risk of prostate cancer. Studies on workers
in Germany
22 and the USA
23 showed a small but statis-
tically signiﬁcant excess in prostate cancer mortality,
based on a limited number of cases. Other studies have
failed to demonstrate this association.
24e26 All former
studies looked at occupation exposure to high concen-
trations in pesticides; however, in our study we speculate
that low concentrations in drinking water supply may
cause PCa, due to the more chronic everyday exposure.
Furthermore, environmental EDCs may affect the
unborn child in the state of organogenesis and cause
signiﬁcant genetic or epigenetic malformations.
In contrast, several recent studies have demonstrated
that PCa may not be related to endogenous androgens.
The Endogenous Hormones and Prostate Cancer
Collaborative Group, analysing
5 18 prospective studies of
3886 men with PCa and 6438 control subjects, found
no associations between PCa risk and serum concentra-
tions of testosterone, calculated free testosterone, dihy-
drotestosterone, dehydroepiandrosterone sulphate,
androstenedione, androstanediol glucuronide, oestra-
diol or calculated free oestradiol. However, this study
investigated serum hormonal levels. EDCs may increase
the risk of PCa by affecting tissue levels or causing
genetic or epigenetic changes that may not be found
Table 1 Multivariable linear regression of the association of mode of contraception and GDP (a measure of country’s wealth)
with prostate cancer (PCa) incidence and PCa mortality
Estimate 95% CI p Value
PCa incidence
Oral contraceptive use 1.06 0.58 to 1.6 <0.001
Intrauterine device 0.01  0.4 to 0.4 0.9
Condom use 0.9  0.1 to 1.9 0.3
Vaginal barrier 0.07  4 to 10 0.5
GDP 0.6 0.1 to 1.1 0.055
PCa mortality
Oral contraceptive use 0.75 0.31 to 1.1 0.06
Intrauterine device  0.02  0.4 to 3 0.2
Condom use 0.2  0.1 to 0.329 0.3
Vaginal barrier 0.01  2.1 to 2 0.9
GDP 0.16 0.04 to 0.9 0.09
GDP, gross domestic product per capita. GDP refers to the market value of all ﬁnal goods and services produced in a country in a given period.
GDP per capita is often considered an indicator of a country’s standard of living.
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Oral contraceptives increase the risk of prostate cancerusing serum levels. Li Tang et al
6 studied the association
between repeat polymorphisms of three key oestrogen-
related genes (CYP11A1, CYP19A1, UGT1A1) and risk of
prostate cancer in the Prostate Cancer Prevention Trial.
The results indicate that repeat polymorphisms in genes
involved in oestrogen biosynthesis and metabolism may
inﬂuence risk of PCa. Further studies are needed to
determine the role of EDCs in PCa.
Some may argue that our results only reﬂect screening
and treatment patterns for prostate cancer, with the
more developed countries having both a higher use of
OCs and a higher incidence of prostate cancer. Unfor-
tunately data on worldwide screening tendencies or
prostate speciﬁc antigen (PSA) use is unavailable.
However, we included a multivariable analysis control-
ling for GDP per capita. GDP refers to the market value
of all ﬁnal goods and services produced in a country in
a given period. GDP per capita is often considered an
indicator of a country’s standard of living. In our
multivariable analysis, OC use was associated with both
incidence and mortality, even when controlling for GDP.
We believe this analysis has strengthened our hypothesis
considerably; however, additional confounding does
exist and should be explored in future studies. Finally,
we cannot report the true levels of EDCs in the water
supply and food chain. We hope such data will be
available in the near future.
In conclusion, we have demonstrated a signiﬁcant
correlation between OC use and prostate cancer inci-
dence and mortality. Classic caseecontrol and cohort
studies may not reveal this association as we are
hypothesising an environmental effect. Tissue correlation
and environmental studies are encouraged.
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APPENDIX 1
A. List of countries included in analysis
Kenya
Mozambique
Uganda
Zambia
Zimbabwe
Angola
Cameroon
Central African Republic
Chad
Congo
Gabon
Egypt
Libyan Arab Jamahiriya
Sudan
Botswana
Namibia
South Africa
Benin
Ghana
Mali
Mauritania
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Oral contraceptives increase the risk of prostate cancerNiger
Nigeria
Senegal
Sierra Leone
Togo
China
Japan
Republic of Korea
Afghanistan
Bangladesh
India
Iran (Islamic Republic of)
Kazakhstan
Pakistan
Tajikistan
Turkmenistan
Uzbekistan
Indonesia
Myanmar
Philippines
Thailand
Viet Nam
Israel
Jordan
Lebanon
Oman
Saudi Arabia
Syrian Arab Republic
Turkey
Yemen
Belarus
Czech Republic
Hungary
Poland
Romania
Russian Federation
Slovakia
Ukraine
Estonia
Finland
Latvia
Lithuania
Norway
Sweden
United Kingdom
Albania
Bosnia and Herzegovina
Italy
Portugal
Spain
Belgium
France
Germany
Switzerland
Mexico
Argentina
Bolivia
Brazil
Chile
Paraguay
Peru
Uruguay
Venezuela (Bolivarian Republic of)
Canada
United States of America
Australia
New Zealand
B. List of Continent analysed
Eastern Africa
Middle Africa
Northern Africa
Southern Africa
Western Africa
Eastern Asia
South-Central Asia
South-Eastern Asia
Western Asia
Eastern Europe
Northern Europe
Southern Europe
Western Europe
Caribbean
Central America
South America
Northern America
Australia/New Zealand
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